More than 600,000 Medicare beneficiaries have registered for GLP-1 weight-loss medications under a federal plan that caps patient costs at $50 monthly. Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz highlighted the success of the program on Monday. Historically, these obesity treatments have been financially inaccessible to many seniors due to their steep prices.

Finance expert Michael Ryan explained to Newsweek, ‘The significant benefit of this program for seniors is converting access to these medications from a potentially huge expense to a manageable $50 monthly decision.’ Ryan added, ‘The enrollment of 600,000 individuals in just two months indicates there was significant demand.’

Why It Matters

GLP-1 medications, such as Wegovy and Zepbound, have revolutionized obesity treatment in recent times. However, their high costs have restricted access for many Americans, especially retirees on fixed incomes. Before the program’s introduction, patients encountered out-of-pocket costs exceeding $1,000 monthly. The recent enrollment reflects a strong desire for affordable GLP-1s among older Americans, which could influence Medicare’s future healthcare spending.

What To Know

On Monday, Dr. Oz noted that approximately 600,000 seniors have already joined the Medicare GLP-1 Bridge program during its initial two months. The initiative launched on July 1 and will continue through December 31, 2027. Eligible beneficiaries can receive covered GLP-1 medications at a flat $50 monthly copayment. The program includes select GLP-1 medications, such as Wegovy, Eli Lilly’s Zepbound in its KwikPen form, and Foundayo, an oral GLP-1 treatment.

However, Ryan warned that the program’s temporary nature could create challenges. ‘The long-term issue is what occurs when people plan their health and household budgets based on this access. This isn’t permanent coverage,’ he said. If Medicare integrates GLP-1 coverage into Part D, the Bridge could serve as a temporary step towards more enduring support. Failure to do so might result in seniors facing increased costs or difficult coverage decisions once accustomed to the $50 payment.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge program is a temporary CMS initiative to increase access to obesity medications for eligible Medicare beneficiaries. Announced in May, the program aims to provide innovative, though expensive, treatments at a predictable monthly rate while assessing the implications of broader coverage on health outcomes and Medicare expenses.

Dr. Oz remarked regarding the program’s launch, ‘These treatments represent significant medical advancement, yet many seniors cannot afford them due to high prices. The Medicare GLP-1 Bridge alters this by making these medications more affordable and accessible, aligning with our broader objective of fostering healthier lives for Americans.’

CMS stated at the program’s commencement that qualifying beneficiaries could acquire covered medications for $50 per month, irrespective of income, until the end of 2027. Chris Klomp, director of Medicare and Chief Counselor at the U.S. Department of Health and Human Services, noted, ‘GLP-1s can dramatically affect patients managing obesity and associated conditions. This demonstration aims to simplify access to these medications, creating more reliable and consistent accessibility across the Medicare program, translating to enhanced quality of life for seniors and better healthcare value.’

Who Qualifies?

According to Medicare, beneficiaries generally need Medicare Part D prescription drug coverage and must meet specific clinical criteria. Eligibility hinges on body mass index (BMI) thresholds and various medical conditions. Qualifying patients may include:

• Individuals with a BMI of 35 or higher.
• Individuals with a BMI of 30 or higher and specific qualifying health conditions.
• Individuals with a BMI of 27 or higher, coupled with specific cardiovascular disease histories or prediabetes.

Some beneficiaries are excluded from the Bridge program. Those eligible for GLP-1 coverage through traditional Medicare Part D, including individuals with Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, should pursue existing drug plan coverage.

Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast, cautioned that high program participation could lead to unanticipated consequences for U.S. healthcare. He noted, ‘If more seniors enroll in these weight-loss medications, it could cause supply disruptions for those with chronic illnesses initially intended for these drugs, even while helping others lose weight.’

What Happens Next

The Medicare GLP-1 Bridge program will be operational until December 31, 2027. Beyond this date, the program’s outlook remains uncertain. CMS will likely evaluate data from the pilot to determine if broader Medicare coverage of obesity medications should persist or undergo modifications. As the enrollment reaches 600,000 beneficiaries after just two months, future costs and health outcomes will probably guide assessments of the program’s effect on patients and Medicare spending.

Thompson expressed concerns about the program’s long-term impacts. He noted, ‘We won’t understand the full repercussions until much later, as these drugs were intended for a smaller diabetic population, not on such a large scale. The real issue arises if and when the program concludes.’ He remarked that some patients might regain weight after discontinuing medication, along with potential digestive side effects. ‘Ultimately, we are expanding the usage of these drugs on a massive scale, and we may not fully grasp the long-term consequences for years,’ Thompson stated.